James A. Schoeneck

James A. Schoeneck (board member) discloses dealings in 3 companies, chiefly Kyntra Bio, Inc., Depomed Inc and Calidi Biotherapeutics, Inc. We count 46 filings; the first trade dates from 18 March 2016 and the latest from 21 August 2025.

On the open market, the record shows 3 purchases worth €311k and 9 sales worth €1.1M. On balance, insiders were net sellers of €815k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 13 share grants and 16 option exercises. 2025 to date brings 3 purchases and no sales.

Half of the purchases are above €101k and half below. 1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 25 August 2025: an open-market purchase of €129k, in Calidi Biotherapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.